Valuation : Alfresa Holdings Corporation

Market Cap 40TCr 262.12Cr 225.84Cr 213.84Cr 193.83Cr 363.63Cr 25TCr 365.47Cr 2.54TCr 976.66Cr 13TCr 984.42Cr 962.82Cr P/E 2027 *
17.5x
P/E 2028 * 14.5x
Enterprise Value 40TCr 262.12Cr 225.84Cr 213.84Cr 193.83Cr 363.63Cr 25TCr 365.47Cr 2.54TCr 976.66Cr 13TCr 984.42Cr 962.82Cr EV / Sales 2027 *
0.13x
EV / Sales 2028 * 0.12x
Free-Float
88.35%
Yield 2027 *
3.09%
Yield 2028 * 3.44%
01/07 Ember LifeSciences, Inc. announced that it has received funding from Alfresa Holdings Corporation CI
22/06 Alfresa Holdings Corporation(TSE:2784) dropped from S&P Japan Mid Cap 100 CI
27/05 ReeNT Co., Ltd. announced that it expects to receive ¥600 million in funding from Alfresa Holdings Corporation CI
27/05 Alfresa Holdings Corporation concluded a share transfer agreement to acquire Nagashima Medical Instruments Co., Ltd. from Nagashima Holdings Co., Ltd. CI
18/05 Alfresa Holdings Corporation's Equity Buyback announced on May 15, 2026, has closed with 6,307,800 shares, representing 3.47% for ¥14,999.95 million. CI
18/05 Tranche Update on Alfresa Holdings Corporation's Equity Buyback Plan announced on May 15, 2026. CI
15/05 Alfresa Holdings Corporation authorizes a Buyback Plan. CI
15/05 Alfresa Holdings Corporation announces an Equity Buyback for 6,307,800 shares, representing 3.46% for ¥14,999.95 million. CI
15/05 Alfresa Holdings Corp - to buy back up to 3.5% of own shares worth about 15 billion yen RE
15/05 Alfresa Holdings Corporation Announces Cash Dividend for the Year-End of the Fiscal Year Ended March 31, 2026, Payable on June 2, 2026; Provides Cash Dividend Guidance for the Second Quarter-End and Year-End of the Fiscal Year Ending March 31, 2027 CI
15/05 Alfresa Holdings Corporation Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2026 and for the Fiscal Year Ending March 31, 2027 CI
07/04 Healios Secures 144 Million Yen Initial Order from Alfresa's Korean Unit for Cosmetic Raw Material MT
27/02 Alfresa Holdings Corporation concluded a share transfer agreement to acquire Techno Suzuta, Co.,Ltd. from Onsendo, K.K. CI
1 week-0.58%
Current month-0.82%
1 month+4.44%
3 months+4.46%
6 months-7.61%
Current year-5.59%
1 week 2,262
Extreme 2262
2,320.5
1 month 2,210.5
Extreme 2210.5
2,351.5
Current year 2,106.5
Extreme 2106.5
2,685.5
1 year 2,055
Extreme 2055
2,685.5
3 years 1,897
Extreme 1897
2,685.5
5 years 1,505
Extreme 1505
2,685.5
10 years 1,505
Extreme 1505
3,350
Manager TitleAgeSince
Chief Executive Officer 63 -
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 63 28/06/2022
Director TitleAgeSince
Director/Board Member 63 01/06/2007
Director/Board Member 65 25/06/2025
Director/Board Member 50 01/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.58%-0.22%-8.49% 262.12Cr
-1.36%-5.89%-23.14%-0.49% 18TCr
-0.72%-3.41%-3.49%+11.74% 12TCr
+0.19%-2.83%+6.20%+80.93% 6.14TCr
-1.92%-6.01%+8.80%+41.11% 4.94TCr
+0.81%-3.73%-6.67%-33.43% 4.84TCr
-1.75%-5.54%+9.25%-22.61% 3.13TCr
+0.43%-11.10% - - 2.86TCr
+0.58%+1.84%+31.28%-12.82% 2.44TCr
+0.49%-7.65%-12.44%+4.86% 2.16TCr
Average -0.33%-4.63%+1.06%+6.75% 5.6TCr
Weighted average by Cap. -0.69%-4.88%-6.04%+10.75%

Financials

2027 *2028 *
Net sales 3,18900Cr 2.08TCr 1.79TCr 1.69TCr 1.54TCr 2.88TCr 1,98300Cr 2.89TCr 20TCr 7.74TCr 1,00900Cr 7.8TCr 7.63TCr 3,28000Cr 2.14TCr 1.84TCr 1.74TCr 1.58TCr 2.96TCr 2,04000Cr 2.98TCr 21TCr 7.96TCr 1,03800Cr 8.02TCr 7.84TCr
Net income 2.35TCr 15Cr 13Cr 12Cr 11Cr 21Cr 1.46TCr 21Cr 148.17Cr 57Cr 743.24Cr 57Cr 56Cr 2.74TCr 18Cr 15Cr 15Cr 13Cr 25Cr 1.7TCr 25Cr 172.56Cr 66Cr 865.58Cr 67Cr 65Cr
Net Debt - -
Logo Alfresa Holdings Corporation
Alfresa Holdings Corporation is a Japan-based holding company primarily engaged in the wholesale of drugs. The Company operates in four business segments. The Pharmaceutical Wholesale segment is engaged in the wholesale of medical products, test reagents, as well as medical equipment and materials. The Self Medication Wholesale segment is engaged in the wholesale of general drugs. The Pharmaceutical Manufacture segment is engaged in the manufacture and sale of pharmaceuticals, test reagents, medical equipment and implements, as well as pharmaceutical powders. The Medical-Related segment is mainly engaged in operation of pharmacies. The others business is engaged in the information system business, the transportation business, the warehousing business, the insurance agency business, the real estate management business, the sale of miscellaneous goods, as well as the manpower dispatching business, among others.
Employees
12,525
Date Price Change Volume
11/26/11 JP¥2,295.00 0.00% 4,71,000
10/26/10 JP¥2,295.00 +0.13% 2,94,100
09/26/09 JP¥2,292.00 +0.33% 3,55,100
08/26/08 JP¥2,284.50 -0.28% 5,83,800
07/26/07 JP¥2,291.00 -0.76% 2,74,700
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
2,295.00JPY
Average target price
2,340.00JPY
Spread / Average Target
+1.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2784 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!